Microwave-assisted synthesis of antimicrobial agents based on pyridazine moiety

References

• Frank H, Heinisch G. Pharmacologically active pyridazines. In: Ellis GP, West GB (Eds). Progress in Medicinal Chemistry. Elsevier; Amsterdam, 1990, 1–49.
   Google Scholar
• Li CS, Brideau C, Chan CC, Savoie C, Cleaveau D, Charleson S, Gordon R, Greig G, Cauthier JY, Lau CK, Riendeau D, Therien M, Wong E, Prasit P. Pyridazinones as selective cyclooxygenase-2 inhibitors. Bioorg Med Chem Lett 2003;13:597–600.
   PubMed Web of Science ®Google Scholar
• Giblin GMP, Bit RA, Brown SH, Chaignot HM, Chowdhury A, Chessel IP, Clayton NM, Coleman T, Hall A, Hammond B, Hurst DN, Michel A, Naylor A, Novelli R, Scocctti T, Spalding D, Tang SP, Wilson AW, Wilson R. The discovery of 6-[2-(5-chloro-2-{[(2,4-difluorophenyl)methyl]oxy}phenyl)-1-cyclopenten-1-yl]-2-pyridinecarboxylic acid, GW848687X, a potent and selective prostaglandin EP1 receptor antagonist for the treatment of inflammatory pain. Bioorg Med Chem Lett 2007;17:385–389.
   PubMedGoogle Scholar
• Dorsch D, Mederski WWKR, Osswald M, Devant RM, Schmitges C-JJS, Christadler M, Wilm C. Pyridazinones with a pendant acylsulfonamide moiety as endothelin receptor antagonists. Bioorg Med Chem 1997;7:275–280.
   Google Scholar
• Nomoto Y, Takai H, Ohno T, Nagashima K, Yao K, Yamada K, Kubo K, Ichimura M, Mihara A, Kase H. Studies of cardiotonic agents. 8. Synthesis and biological activities of optically active 6-(4-(benzylamino)-7-quinazolinyl)-4,5-dihydro-5-methyl-3(2H)-pyridazinone (KF15232). J Med Chem 1996;39:297–303.
   PubMedGoogle Scholar
• Barbaro R, Betti I, Botta M, Corelli F, Giannaccini G, Maccari I, Manetti F, Strappaghetti G, Corsano S. Synthesis, biological evaluation, and pharmacophore generation of new pyridazinone derivatives with affinity toward α(1)- and α(2)-adrenoceptors. J Med Chem 2001;44:2118–2132.
   PubMed Web of Science ®Google Scholar
• Kandile NG, Mohamed MI, Zaky H, Mohamed HM. Novel pyridazine derivatives: Synthesis and antimicrobial activity evaluation. Eur J Med Chem 2009;44:1989–1996.
   PubMed Web of Science ®Google Scholar
• Husain A, Ahmad A, Mujeeb M, Akhter M. New amides of sulphonamides: synthesis and biological evalution. Chil J Chem Soc 2010;55:74–77.
   Google Scholar
• Husain A. Amide derivatives of sulfonamides and isoniazid: synthesis and biological evaluation. Acta Pol Pharm 2009;66:513–521.
   PubMed Web of Science ®Google Scholar
• Drews J. Drug discovery: a historical perspective. Science 2000;287:1960–1964.
   PubMed Web of Science ®Google Scholar
• Supuran CT, Scozzafava A. Carbonic anhydrase inhibitors and their therapeutic potential. Exp Opin Ther Patents 2000;10:575–600.
   Web of Science ®Google Scholar
• Supuran CT, Scozzafava A. Carbonic anhydrase inhibitors. Curr Med Chem-Immunol Endocr Metabol Agents 2001;1:61–97.
   Google Scholar
• Maren TH. Relatons between structure and biological activity of sulfonamides. Annu Rev Pharmacol Toxicol 1976;16:309–327.
   PubMed Web of Science ®Google Scholar
• Boyd AE 3rd. Sulfonylurea receptors, ion channels, and fruit flies. Diabetes 1988;37:847–850.
   PubMed Web of Science ®Google Scholar
• Thornber CW. Isosterism and molecular modification in drug design. Chem Soc Rev 1979;8:563–580.
   Web of Science ®Google Scholar
• Ogden RC, Flexner CW. ( Eds.) Protease Inhibitors in AIDS Therapy. New York: Marcel Dekker, 2001.
   Google Scholar
• Scozzafava A, Mastrolorenzo A, Supuran CT. Agents that target cysteine residues of biomolecules and their therapeutic potential. Exp Opin Ther Patents 2001;11:765–787.
   Web of Science ®Google Scholar
• Scozzafava A, Supuran CT. Carbonic anhydrase and matrix metalloproteinase inhibitors: sulfonylated amino acid hydroxamates with MMP inhibitory properties act as efficient inhibitors of CA isozymes I, II, and IV, and N-hydroxysulfonamides inhibit both these zinc enzymes. J Med Chem 2000;43:3677–3687.
   PubMed Web of Science ®Google Scholar
• Casini A, Scozzafava A, Mastrolorenzo A, Supuran LT. Sulfonamides and sulfonylated derivatives as anticancer agents. Curr Cancer Drug Targets 2002;2:55–75.
   PubMed Web of Science ®Google Scholar
• Dua R, Shrivastava S, Sonwane SK, Srivastava SK. Pharmacological significance of synthetic heterocycles scaffold: a review. Advan Biol Res 2011;5:120–144.
   Google Scholar
• Zaky HT, Mohamed MI, Nail AM, Kandile NG. Synthesis of some novel biologically active sulphonamides. Egypt J Chem 2004;47:321–331.
   Google Scholar
• Mohamed MI. Synthesis and antimicrobial activity of new pyridazinyl sulfonamide derivatives. Bulg Chem Commun 2007;39:152–158.
   Web of Science ®Google Scholar
• Bahrami K, Khodaei MM, Soheilizad M. Direct conversion of thiols to sulfonyl chlorides and sulfonamides. J Org Chem 2009;74:9287–9291.
   PubMedGoogle Scholar
• Mohamed MI, Zaky HT, Mohamed HM, Kandile NG. Novel heterocyclic systems of pyridazines. Afinidad 2005;62:48–56.
   Web of Science ®Google Scholar
• Zolfigola MA, Khazaeia A, Moosavi-Zarea AR, Zareb A. 3-Methyl-1-sulfonic acid imidazolium chloride as a new, efficient and recyclable catalyst and solvent for the preparation of N-sulfonyl imines at room temperature. J Iran Chem Soc 2010;7:646–651.
   Google Scholar
• Ahmad S, Rathish IG, Bano S, Alam MS, Javed K. Synthesis and biological evaluation of some novel 6-aryl-2-(p-sulfamylphenyl)-4,5-dihydropyridazin-3(2H)-ones as anti-cancer, antimicrobial, and anti-inflammatory agents. J Enzyme Inhib Med Chem 2010;25:266–271.
   PubMed Web of Science ®Google Scholar
• Tading H, Mohamed E, Asres K, Gebre T. Antimicrobial activities of some selected traditional Ethiopian medicinal plants used in the treatment of skin disorders. J Ethnopharmacol 2005;100:168–175.
   PubMedGoogle Scholar
• Karthikeyan SM, Prasad JD, Mahalinga M, Holla SB, Kumari SB. Antimicrobial studies of 2,4-dichloro-5-fluorophenyl containing oxadiazoles. Eur J Med Chem 2008;43:25–31.
   PubMed Web of Science ®Google Scholar